ONE NUCLEUS STRENGTHENS BOARD WITH APPOINTMENT OF NEW DIRECTOR

Life Sciences industry leader joins the region’s Life Science & Healthcare membership organisation
Cambridge, UK: 10 April 2024

Life Sciences industry leader joins the region’s Life Science & Healthcare membership organisation
Cambridge, UK: 10 April 2024
We are seeking a talented and creative Senior Bioinformatician with a passion for using computational advances to prioritise and advance high-potential therapeutic antibodies and targets from Alchemab’s discovery platform through to the clinic.
Reporting into the Principal Bioinformatician, the Senior Bioinformatician will take a lead role in shaping and executing Alchemab’s computational target evaluation strategy by:
Healx is an AI-powered tech bio company that is redesigning drug discovery. With 10,000 rare diseases affecting 400 million people globally, 90% of which have no approved treatment, Healx is on a mission to pioneer the next generation of drug discovery to help rare disease patients in need. We combine data, artificial intelligence and deep pharmacology expertise to develop treatments more quickly and cheaply than traditional drug discovery.
Healx is an AI-powered tech bio company that is redesigning drug discovery. With 10,000 rare diseases affecting 400 million people globally, 90% of which have no approved treatment, Healx is on a mission to pioneer the next generation of drug discovery to help rare disease patients in need. We combine data, artificial intelligence and deep pharmacology expertise to develop treatments more quickly and cheaply than traditional drug discovery.
Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development.
At AstraZeneca's Oncology R&D department, we follow the science and pioneer new frontiers. We are a team dedicated to Oncology Cell Therapies, with an ambition to eliminate cancer as a cause of death. Our big vision unites and inspires us. With multiple indications and cutting-edge therapeutic modalities at all stages of our innovative pipeline, we keep pushing forward. Fusing groundbreaking science with the latest technology to achieve breakthroughs.
We are now seeking applications for an experienced Staff Scientist to actively contribute to exciting work. The post will be part of a dynamic group, led by Prof Jesmond Dalli, and will support the translational collaborative efforts to understand pathological mechanisms contributing to musculoskeletal diseases as part of a NIHR funded Biomedical Research Centre. The successful candidate is likely to be an energetic, focused, and productive individual with a desire to work in a congenial, dynamic, and collaborative research environment.
About Iso
Isomorphic Labs (IsoLabs) was launched in 2021 to advance human health by building on and beyond the Nobel-winning AlphaFold system. Since then, our interdisciplinary team of drug discovery experts and machine learning specialists has built powerful new predictive and generative AI models that accelerate scientific discovery at digital speed.
UCL's Vice-Provost (Health) is advancing a new UCL Health Strategy that both sustains our centres of excellence and invests in strategic opportunity areas to create impact at scale with our partners. Supported by the £11.9m UCLH Strategic Research Fund (SRF)-and aligned with the NIHR UCLH Biomedical Research Centre (BRC) goals to drive innovation and clinical impact-this investment is strengthening research capacity and developing new facilities across UCLH and UCL. We are now recruiting three Strategic Leaders to drive ambitious, cross‑disciplinary programmes in:
Tokyo, Japan and Cambridge, UK, 5 March 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that Centessa Pharmaceuticals has achieved an additional early development milestone associated with its investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist, ORX489, being developed by Centessa for the treatment of neuropsychiatric disorders. This milestone triggers a payment of US $3 million to Nxera pursuant to its research collaboration with Centessa.